Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
about
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.Bevacizumab in ovarian cancer: A critical review of phase III studiesMajor clinical research advances in gynecologic cancer in 2015A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyMRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsLong noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients.A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancerFactors favouring long-term survival following recurrence in ovarian cancer.Association of financial status and the quality of life in Chinese women with recurrent ovarian cancerHIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD ConsortiumBTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosisDerivation and characterization of matched cell lines from primary and recurrent serous ovarian cancerA parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.Preoperative serum tumor marker levels in gastric cancer.Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosisPlatinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patientsRadical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study.Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Retrospective Study of 164 Cases.Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma.The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling.High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancerBRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor MarkersVascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort StudyA phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survivalSignificance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma.Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
P2860
Q27692699-BFECEB7A-725E-4BB9-849C-42FC7C37B468Q27853088-C09BF33C-B935-4551-80ED-666FDFF3F41BQ28076188-1B928064-1B1E-48EA-8342-298EA30F608CQ28077183-8A61E317-8153-4FD0-B4E0-C39E0F38D3D2Q30355928-1A7B8239-EF35-4573-B8AC-A6A6154B6956Q30358635-4733FCE9-66E0-4320-BFA5-2D2D2C0235D9Q30374367-E96E6D5E-F425-44AC-BCFE-675D3204E463Q30411910-1BC92C61-46D2-4C0D-9DD0-F3378C80D48AQ30881669-1F9BE51C-B73F-474D-AE47-C96A2EEB206BQ33401443-AA97AA67-352A-402C-B018-0718DD1FE27EQ33410746-7E8DF5CF-C51F-41AF-9056-E53224340B91Q33441574-553134FC-BFF4-4808-B8D2-0A68A387DBAAQ33651605-68507AB1-F66A-4C85-B1AE-19ED631FE59CQ33671544-4BE315B0-5444-4F2E-A01E-033974751800Q33786353-77A083FB-CC68-4571-917A-B1811DF940F6Q33857691-C1D1D226-B995-49A6-A7A5-4D745743B827Q33908900-5304E1C1-3835-48E2-88ED-2790D0AB0E79Q34198666-AD7EF146-4258-4852-A33B-07A9DF61AA97Q34299655-4B81E9D4-E35F-413B-97DB-F9802041787DQ34397197-111F55C8-023F-4BFD-9BA4-5E7CE3E2D75AQ34499662-C333FF49-00EE-4BD7-ABFE-24CBFA13D6DAQ34660420-087F434A-4B0F-421C-B585-4D8ED5D2735DQ34783507-A7ED75FB-C7D5-45E3-917E-02AA3C7EE489Q35177861-F6CAC5ED-D4C6-4B11-8B9C-01A76FBBA1FAQ35744585-870D8C08-1A14-456C-9048-96F5653F16C7Q35830931-CE0AA2A9-3853-43B7-9258-E1F7891D9763Q35857892-CA989FD4-EA5C-43BB-8345-FF893437CB1DQ35929423-26E4F564-B0A4-4785-A255-8E5F456C88B7Q36039632-8C3E5A71-7D17-4751-9260-4F2F44E497E3Q36057106-7957E8C5-31D0-46AB-B60A-551153F6758CQ36145443-A2717A4B-C759-4A77-B076-C25D82D3A745Q36240562-69091D96-7910-4E41-B9AD-0AD4E43D6388Q36372283-4FC5C2C8-4713-4B06-9E2D-7FEB3BD32310Q36414088-9AC04701-DC0C-45C2-885D-2373F64A977FQ36482461-CAC11194-DFC3-4E28-80FB-3C300CF51021Q36544827-EBF45CB5-922E-4EFF-8FFE-E117D04F41B2Q36546798-A867DFAB-607D-44CB-BFA2-85F02C4AD257Q36752512-106F5616-1FC2-455A-B3D3-5B6FBC4FF7A8Q36923202-9548A711-BAC8-4EEC-B354-081A0C49F847Q36960802-71BF6926-8608-446E-BA94-EAEE39F034DC
P2860
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Definitions for response and p ...... ical Cancer Intergroup (GCIG).
@en
Definitions for response and p ...... ynecological Cancer Intergroup
@nl
type
label
Definitions for response and p ...... ical Cancer Intergroup (GCIG).
@en
Definitions for response and p ...... ynecological Cancer Intergroup
@nl
prefLabel
Definitions for response and p ...... ical Cancer Intergroup (GCIG).
@en
Definitions for response and p ...... ynecological Cancer Intergroup
@nl
P2093
P1476
Definitions for response and p ...... ical Cancer Intergroup (GCIG).
@en
P2093
Anders Jakobsen
Andreas du Bois
Andres Cervantes
Elizabeth Eisenhauer
Gordon John Sampson Rustin
Gunnar Kristensen
Gynecological Cancer Intergroup
Jan Vermorken
Kathryn Greven
Mahesh Parmar
P304
P356
10.1097/IGC.0B013E3182070F17
P577
2011-02-01T00:00:00Z